VBIV News and Press, VBI Vaccines Inc. From 04/04/23

VBI will continue to heavily prioritize making a difference in both prevention and treatment of hepatitis B (HBV) with PreHevbrio™ [Hepatitis B Vaccine (Recombinant)] and immunotherapeutic candidate VBI-2601 Cost-saving measures expected to reduce quarterly operating expenses and headc...

Access to PreHevbrio [Hepatitis B Vaccine (Recombinant)] continues to broaden in the U.S. and beyond, with additional approvals received in 2022 in Europe and Canada Clinical data expected throughout 2023 from: (i) VBI-2601: two ongoing Phase II studies in chronically infected hepatitis B (HB...

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, VBI’s President and CEO, and David E. Anderson, VBI’s Chief Scientific Officer, will discuss t...

BI-2601 (BRII-179) and BRII-835 combination was generally well-tolerated with no new safety signals observed Initial data suggest VBI-2601 (BRII-179) and BRII-835 combination induced meaningfully stronger anti-hepatitis B surface antigen (HBsAg)-specific T-cell and antibody responses compared...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . For further details see: Wall Street Breakfast: Shifting Gears

Health Canada has approved VBI Vaccines' ( NASDAQ: VBIV ) hepatitis B vaccine PreHevbrio . The approval is the fourth for the triple-antigen shot. Approval was based on data from two phase 3 trials that compared PreHevbrio to GlaxoSmithKline's ( GSK ) Engerix-B, a sin...

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Health Canada has approved PreHevbrio ™ [3-antigen Hepatitis B Vaccine (Recombinant)] for active immunization ag...

CEPI and VBI expand scope of partnership to target multiple coronavirus threats Vaccine platform presents multiple antigens, mimicking natural form of the virus The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its world-leading portfolio of potential var...

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that additional biomarker data from the Phase 1/2a study of VBI-1901, the Company’s cancer vaccine immunotherap...

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that its abstract highlighting data from the ongoing Phase 2a study of VBI-1901, the Company’s cancer vaccine i...